-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 8, Revance Therapeutics announced fda approval of Daxify (DaxibotulinumtoxinA-lanm for injection) for the temporary improvement of moderate to severe frown lines (interbrush lines)
TransMTs Technology Platform Stabilized Peptide Formulations and Highly Purified Botulinum Toxin Type A are the first and only long-acting peptide formulation neuromodulators with a median duration of 6 months and up to 9 months
The approval is based on data from a Phase III clinical trial code-named SAKURA, which included more than 2,700 patients
Source: Revance's official website
In terms of safety, the study did not report serious treatment-related adverse events, and its safety is consistent